Effect of bilateral superficial parotid gland sparing IMRT on xerostomia and QOL: A prospective study.
Humans
Xerostomia
/ etiology
Quality of Life
Parotid Gland
/ radiation effects
Female
Male
Radiotherapy, Intensity-Modulated
/ adverse effects
Middle Aged
Prospective Studies
Adult
Head and Neck Neoplasms
/ radiotherapy
Aged
Radiotherapy Dosage
Organ Sparing Treatments
/ methods
Surveys and Questionnaires
Treatment Outcome
Journal
Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
received:
03
10
2022
accepted:
30
01
2023
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
16
10
2024
Statut:
ppublish
Résumé
Superficial lobe constitutes 80% of the parotid and is situated lateral to mandible and can be better spared during intensity modulated radiation therapy (IMRT) for head and neck cancer (HNC). This study aimed to see the impact of bilateral superficial parotid gland (PG) sparing IMRT on xerostomia and quality of life (QOL) in patients with HNC receiving radiation. Prospective, questionnaire-based study. Thirty-four patients with histopathologically proven non-nasopharyngeal non-oral cavity HNC were included in this study. IMRT technique was used and a constraint of 24 Gy was given to combined superficial PG. Physician- and patient-rated xerostomia and QOL scores were recorded at baseline and two weeks, three months, and six months post-radiation therapy (RT). The combined superficial PG dose correlated with xerostomia and QOL scores. The combined superficial PG and combined whole PG mean dose was 18.71 Gy and 30 Gy, respectively, and the difference was statistically significant (P-< 0.001). At two weeks, three months, and six months post-RT, the odds of xerostomia scores were 0.11, 0.071, 0.042, respectively for a median dose of <18 Gy compared to >18 Gy and was statistically significant P=(0.001). Bilateral superficial PG sparing IMRT is beneficial in reducing xerostomia and translates to a better QOL.
Sections du résumé
BACKGROUND
BACKGROUND
Superficial lobe constitutes 80% of the parotid and is situated lateral to mandible and can be better spared during intensity modulated radiation therapy (IMRT) for head and neck cancer (HNC). This study aimed to see the impact of bilateral superficial parotid gland (PG) sparing IMRT on xerostomia and quality of life (QOL) in patients with HNC receiving radiation.
STUDY DESIGN
METHODS
Prospective, questionnaire-based study.
MATERIALS AND METHODS
METHODS
Thirty-four patients with histopathologically proven non-nasopharyngeal non-oral cavity HNC were included in this study. IMRT technique was used and a constraint of 24 Gy was given to combined superficial PG. Physician- and patient-rated xerostomia and QOL scores were recorded at baseline and two weeks, three months, and six months post-radiation therapy (RT). The combined superficial PG dose correlated with xerostomia and QOL scores.
RESULTS
RESULTS
The combined superficial PG and combined whole PG mean dose was 18.71 Gy and 30 Gy, respectively, and the difference was statistically significant (P-< 0.001). At two weeks, three months, and six months post-RT, the odds of xerostomia scores were 0.11, 0.071, 0.042, respectively for a median dose of <18 Gy compared to >18 Gy and was statistically significant P=(0.001).
CONCLUSION
CONCLUSIONS
Bilateral superficial PG sparing IMRT is beneficial in reducing xerostomia and translates to a better QOL.
Identifiants
pubmed: 39412906
doi: 10.4103/jcrt.jcrt_2072_22
pii: 01363817-202420050-00008
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1400-1405Informations de copyright
Copyright © 2024 Copyright: © 2024 Journal of Cancer Research and Therapeutics.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
Prabhash K, Babu G, Chaturvedi P, Kuriakose M, Birur P, Anand AK, et al. Indian clinical practice consensus guidelines for the management of squamous cell carcinoma of head and neck. Indian J Cancer 2020; 57 (Supplement) S1–5.
Pignon JP, Maitre AL, Maillard E, Jean B Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4–14.
Yadaraju VA, Gururajachar JM, Jyosthna Elagandula J, Sreenivasa KKA Comprehensive assessment of xerostomia in patients receiving radiation for head and neck cancer. Int J Cancer Ther Oncol 2016; 4: 4216.
Gupta T, Sinha S, Ghosh-Laskar S, Budrukkar A, Mummudi N, Swain M, et al. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: Long-term and mature outcomes of a prospective randomized trial. Radiat Oncol 2020; 15: 218.
Van Rij CM, Oughlane-Heemsbergen WD, Ackerstaff AH, Lamers EA, Balm AJM, Rasch CRN Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. Radiat Oncol 2008; 3: 41.
Miah AB, Gulliford SL, Morden J, Newbold KL, Bhide SA, Zaidi SH, et al. Recovery of salivary function: Contralateral parotid-sparing intensity-modulated radiotherapy versus bilateral superficial lobe parotid-sparing intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 2016; 28: e69–76.
Luijk PV, Pringle S, Deasy JO, Moiseenko VV, Faber H, Hovan A, et al. Sparing the region of the salivary gland containing stem cells preserves saliva production after radiotherapy for head and neck cancer. Sci Transl Med 2015; 7: 1–8.
Nevens D, Nuyts S Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy for head and neck cancer?. Br J Radiol 2017; 90: 20170596.
Miah AB, Schick U, Bhide SA, Guerrero-Urbano M-T, Clark CH, Bidmead AM, et al. A phase II trial of induction chemotherapy and chemo-IMRT for head and neck squamous cell cancers at risk of bilateral nodal spread: The application of a bilateral superficial lobe parotid-sparing IMRT technique and treatment outcomes. Br J Cancer 2015; 112: 32–8.
Miah AB, Bhide SA, Guerrero-Urbano MT, Clark C, Newbold KL, Harrington KJ, et al. Bilateral superficial parotid gland sparing IMRT produces similar long-term xerostomia scores when compared to unilateral parotid sparing IMRT in Midline head and neck squamous cell cancers (HNSCC). Int J Radiat Oncol Biol Phys 2009; 75: S401.
Zhang HB, Lu X, Huang SM, Wang L, Zhao C, Xia WX, et al. Superficial parotid lobe-sparing delineation approach: A better method of dose optimization to protect the parotid gland in intensity-modulated radiotherapy for nasopharyngeal carcinoma. Curr Oncol 2013; 20: e577–84.
Cox JD, Stetz J, Pajak TF Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341–6.
Sherman AC, Simonton S, Adams DC, Vural E, Owens B, Hanna E Assessing quality of life in patients with head and neck cancer: Cross-validation of the European organization for research and treatment of cancer (EORTC) quality of life head and neck module (QLQ-H&N35). Arch Otolaryngol Head Neck Surg 2000; 126: 459–67.
Memtsa PT, Tolia M, Tzitzikas I, Bizakis I, Pistevou-Gombaki K, Charalambidou M, et al. Validity and reliability of the Greek version of the xerostomia questionnaire in head and neck cancer patients. Support Care Cancer 2017; 25: 847–53.
Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127–36.
Doaa MALZ, Ehab MA, Abouelenein HS, Shady F, Wafaa K Dosimetric comparison of intensity-modulated radiotherapy versus 3d conformal radiotherapy in patients with head and neck cancer. J Multidiscipl Eng Sci Technol 2015; 2: 678–82.